^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BT1718

    i
    Other names: BT1718, BT-1718, BT 1718, MMP14-DM1 peptide drug conjugate
    Associations

    News

    Trials
    Company:
    Bicycle Therap
    Drug class:
    Microtubule inhibitor, MMP-14 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Development and Evaluation of [68Ga]Ga-DOTA-BT1718: A Novel Imaging Agent Targeting MT1-MMP for Malignant Tumor Diagnosis. (PubMed, J Med Chem)
    Notably, this difference was significant (p < 0.05). Preliminary clinical translation results demonstrated that &lsqb;68Ga]Ga-DOTA-BT1718 exhibited significant uptake in patients with pancreatic cancer and glioma, indicating its great potential for clinical application.
    Journal
    |
    MMP14 (Matrix Metallopeptidase 14)
    |
    BT1718
    almost2years
    CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov)
    P1/2, N=72, Completed, Cancer Research UK | Active, not recruiting --> Completed
    Trial completion
    |
    MMP14 (Matrix Metallopeptidase 14)
    |
    BT1718
    over2years
    CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov)
    P1/2, N=72, Active, not recruiting, Cancer Research UK | Recruiting --> Active, not recruiting | N=130 --> 72
    Enrollment closed • Enrollment change • Metastases
    |
    MMP14 (Matrix Metallopeptidase 14)
    |
    BT1718
    over3years
    CRUKD/17/009: BT1718 in Patients With Advanced Solid Tumours. (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Cancer Research UK | Trial completion date: Mar 2022 --> Dec 2024 | Trial primary completion date: Mar 2022 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    MMP14 (Matrix Metallopeptidase 14)
    |
    BT1718